DB
BIO icon

Dmitry Balyasny’s Bio-Rad Laboratories Class A BIO Stock Holding History

Dmitry Balyasny’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-47,073
Closed -$15.5M – 2801
2024
Q4 		$15.5M Buy
+47,073
New +$16M 0.02% 772
2024
Q1 		– Sell
-15,730
Closed -$5.08M – 2627
2023
Q4 		$5.08M Buy
+15,730
New +$4.93M 0.01% 1106
2023
Q1 		– Sell
-67,043
Closed -$28.2M – 2665
2022
Q4 		$28.2M Buy
+67,043
New +$27.1M 0.08% 343
2022
Q3 		– Sell
-54,343
Closed -$26.9M – 2858
2022
Q2 		$26.9M Sell
54,343
-28,464
-34% -$14.8M 0.09% 325
2022
Q1 		$46.6M Buy
82,807
+32,082
+63% +$19.3M 0.15% 161
2021
Q4 		$38.3M Buy
+50,725
New +$38M 0.13% 204
2021
Q3 		– Sell
-50,518
Closed -$37.8M – 1948
2021
Q2 		$32.5M Buy
+50,518
New +$30.7M 0.15% 162
2021
Q1 		– Sell
-19,522
Closed -$11.4M – 1765
2020
Q4 		$11.4M Buy
19,522
+11,634
+147% +$6.63M 0.06% 406
2020
Q3 		$4.07M Sell
7,888
-19,194
-71% -$9.72M 0.03% 669
2020
Q2 		$12.2M Buy
+27,082
New +$12M 0.11% 294
2018
Q4 		– Sell
-8,956
Closed -$2.8M – 1410
2018
Q3 		$2.8M Sell
8,956
-25,133
-74% -$7.8M 0.01% 888
2018
Q2 		$9.84M Sell
34,089
-8,324
-20% -$2.3M 0.04% 491
2018
Q1 		$10.6M Buy
42,413
+41,355
+3,909% +$10.5M 0.04% 508
2017
Q4 		$253K Buy
+1,058
New +$256K ﹤0.01% 1810
2017
Q3 		– Sell
-1,644
Closed -$372K – 1883
2017
Q2 		$372K Sell
1,644
-23,566
-93% -$5.14M ﹤0.01% 1271
2017
Q1 		$5.03M Buy
25,210
+4,486
+22% +$864K 0.02% 703
2016
Q4 		$3.78M Buy
+20,724
New +$3.53M 0.02% 762
2016
Q2 		– Sell
-1,600
Closed -$219K – 1168
2016
Q1 		$219K Buy
+1,600
New +$210K ﹤0.01% 1099
2015
Q4 		– Sell
-1,612
Closed -$217K – 1238
2015
Q3 		$217K Buy
+1,612
New +$232K ﹤0.01% 996

Other funds holding BIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Dmitry Balyasny's BIO Position: Q1 2025 in Review

Dmitry Balyasny sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2025, closing a stake of 47,073 shares — an estimated $15.5M sold.

Dmitry Balyasny first reported a position in BIO in Q3 2015 and held it in 19 quarters. The position peaked at $46.6M in Q1 2022. 436 funds tracked by Wall St. Rank hold BIO as of Q1 2025.

  • Dmitry Balyasny reported no remaining Bio-Rad Laboratories Class A position as of Q1 2025 after selling out during the quarter.
  • Dmitry Balyasny sold 47,073 Bio-Rad Laboratories Class A shares in Q1 2025, an estimated $15.5M.
  • Dmitry Balyasny first reported a position in Bio-Rad Laboratories Class A in Q3 2015 and held it in 19 quarters.
  • Dmitry Balyasny's Bio-Rad Laboratories Class A position peaked at $46.6M in Q1 2022.
  • 436 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2025.

Based on Balyasny Asset Management's 13F filing for Q1 2025, filed 15 May 2025.